Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.

Abstract

OBJECTIVE:

The efficacy of mogamulizumab in adult T-cell leukemia/lymphoma (ATLL) was reported in a previous phase 2 study. Compared with patients in clinical trials, however, most patients in real-life settings have demonstrated worse outcomes.

METHOD:

We retrospectively analyzed 96 patients with relapsed/refractory ATLL who received mogamulizumab treatment.

RESULTS:

Relapsed/refractory ATLL patients with a median age of 70 years received a median of five courses of mogamulizumab. Hematologic toxicity and skin rash were the most common adverse events, and both were manageable. Of 96 patients, 87 were evaluable for efficacy. The overall response rate was 36%, and the median progression-free survival (PFS) and overall survival (OS) from the start of mogamulizumab therapy were 1.8 and 4.0 months, respectively. Of the original 96 patients, only 25 fulfilled the inclusion criteria of the phase 2 study. Those who met the criteria demonstrated longer median PFS and OS durations of 2.7 and 8.5 months, respectively. The median OS from diagnosis in relapsed/refractory ATLL patients receiving mogamulizumab was 12 months, longer than the 5.8 months in a historical cohort without mogamulizumab.

CONCLUSION:

In clinical practice, mogamulizumab exhibited antitumor activity in patients with relapsed/refractory ATLL, with an acceptable toxicity profile. Mogamulizumab therapy improved the OS of ATLL patients.

• Authors: Masaaki Sekine, Yoko Kubuki, Takuro Kameda, Masanori Takeuchi, Takanori Toyama, Noriaki Kawano, Kouichi Maeda, Seiichi Sato, Junzo Ishizaki, Hiroshi Kawano, Ayako Kamiunten, Keiichi Akizuki, Yuki Tahira, Haruko Shimoda, Kotaro Shide, Tomonori Hidaka, Akira Kitanaka, Kiyoshi Yamashita, Hitoshi Matsuoka, Kazuya Shimoda
• Journal: European journal of haematology (Eur J Haematol) Vol. 98 Issue 5 Pg. 501-507 (May 2017) ISSN: 1600-0609 [Electronic] England
• PMID: 28152225 (Publication Type: Journal Article)
• Copyright: © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Chemical References

• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents, Immunological
• mogamulizumab

Topics

• Adult
• Aged
• Aged, 80 and over
• Antibodies, Monoclonal, Humanized (administration & dosage, adverse effects, therapeutic use)
• Antineoplastic Agents, Immunological (administration & dosage, adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Drug Resistance, Neoplasm
• Female
• Humans
• Leukemia-Lymphoma, Adult T-Cell (drug therapy, mortality, pathology)
• Male
• Middle Aged
• Recurrence
• Retreatment
• Retrospective Studies
• Survival Analysis
• Treatment Outcome